Shares of Anthem Biosciences Ltd., a specialized fermentation-based APIs manufacturer, made a strong debut on the stock exchanges today, listing at ₹723.05, around 26.85% higher than its issue price of ₹570 per share. The stock is now trading on both the BSE (Script Code: 544449) and NSE (Code: ANTHEM) under the ‘B’ Group of Securities.
The ₹3,395 crore IPO, which was open for subscription from July 14 to July 16, had received overwhelming demand from investors, being subscribed a robust 63.86 times overall. The Qualified Institutional Buyers (QIB) segment was the most aggressive, subscribing 182.65 times, while Non-Institutional Investors (NIIs) and retail investors subscribed 42.36 times and 5.64 times, respectively.
The public issue was purely an Offer for Sale (OFS) of 5.96 crore equity shares, with no fresh issue component.
On listing, the company’s market cap surged, reflecting strong investor confidence backed by its leadership position in the specialized fermentation-based active pharmaceutical ingredients (APIs) sector.
Key details:
-
IPO price: ₹570 per share
-
Listing price: ₹723.05 per share (around 27% gain)
-
Issue size: ₹3,395 crore
-
Subscription: 63.86x overall
-
QIBs: 182.65x
-
NIIs: 42.36x
-
Retail: 5.64x
-
Book-running lead manager: JM Financial
Registrar to the issue: Kfin Technologies
The strong debut comes on the back of solid fundamentals, robust order book, and high investor interest during the IPO period. Market participants will now keenly watch how the stock performs in the coming days as trading stabilizes post-listing.
